The 36-month beta value for RGEN is also noteworthy at 1.21. There are mixed opinions on the stock, with 9 analysts rating it as a “buy,” 4 rating it as “overweight,” 6 rating it as “hold,” and 0 rating it as “sell.”
The public float for RGEN is 53.02M, and at present, short sellers hold a 6.68% of that float. The average trading volume of RGEN on April 17, 2025 was 756.37K shares.
RGEN) stock’s latest price update
The stock of Repligen Corp (NASDAQ: RGEN) has increased by 4.33 when compared to last closing price of 126.62.Despite this, the company has seen a gain of 6.66% in its stock price over the last five trading days. zacks.com reported 2025-04-16 that Investors interested in Medical – Biomedical and Genetics stocks are likely familiar with Genmab A/S Sponsored ADR (GMAB) and Repligen (RGEN). But which of these two stocks is more attractive to value investors?
RGEN’s Market Performance
RGEN’s stock has risen by 6.66% in the past week, with a monthly drop of -8.48% and a quarterly drop of -16.01%. The volatility ratio for the week is 7.13% while the volatility levels for the last 30 days are 7.31% for Repligen Corp. The simple moving average for the past 20 days is 2.82% for RGEN’s stock, with a -9.07% simple moving average for the past 200 days.
Analysts’ Opinion of RGEN
Many brokerage firms have already submitted their reports for RGEN stocks, with Evercore ISI repeating the rating for RGEN by listing it as a “In-line.” The predicted price for RGEN in the upcoming period, according to Evercore ISI is $155 based on the research report published on March 18, 2025 of the current year 2025.
TD Cowen, on the other hand, stated in their research note that they expect to see RGEN reach a price target of $200. The rating they have provided for RGEN stocks is “Buy” according to the report published on February 10th, 2025.
Canaccord Genuity gave a rating of “Hold” to RGEN, setting the target price at $165 in the report published on December 17th of the previous year.
RGEN Trading at -7.78% from the 50-Day Moving Average
After a stumble in the market that brought RGEN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -27.62% of loss for the given period.
Volatility was left at 7.31%, however, over the last 30 days, the volatility rate increased by 7.13%, as shares sank -8.82% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -17.45% lower at present.
During the last 5 trading sessions, RGEN rose by +6.66%, which changed the moving average for the period of 200-days by +4.79% in comparison to the 20-day moving average, which settled at $128.48. In addition, Repligen Corp saw -8.23% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RGEN starting from Hunt Anthony, who sale 26,756 shares at the price of $152.51 back on Mar 17 ’25. After this action, Hunt Anthony now owns 136,301 shares of Repligen Corp, valued at $4,080,663 using the latest closing price.
Pax Margaret, the Director of Repligen Corp, purchase 250 shares at $150.69 during a trade that took place back on Mar 17 ’25, which means that Pax Margaret is holding 1,043 shares at $37,672 based on the most recent closing price.
Stock Fundamentals for RGEN
Current profitability levels for the company are sitting at:
- -0.07 for the present operating margin
- 0.49 for the gross margin
The net margin for Repligen Corp stands at -0.05. The total capital return value is set at -0.02. Equity return is now at value -1.30, with -0.90 for asset returns.
Based on Repligen Corp (RGEN), the company’s capital structure generated 0.25 points at debt to capital in total, while cash flow to debt ratio is standing at 0.26. The debt to equity ratio resting at 0.34. The interest coverage ratio of the stock is -2.57.
Currently, EBITDA for the company is 113.34 million with net debt to EBITDA at -0.7. When we switch over and look at the enterprise to sales, we see a ratio of 11.7. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.41.
Conclusion
In summary, Repligen Corp (RGEN) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
